Search Results - "Di, Henna A."

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy by Hirayama, Alexandre V., Chou, Cassie K., Miyazaki, Takahiro, Steinmetz, Rachel N., Di, Henna A., Fraessle, Simon P., Gauthier, Jordan, Fiorenza, Salvatore, Hawkins, Reed M., Overwijk, Willem W., Riddell, Stanley R., Marcondes, Mario Q., Turtle, Cameron J.

“…•Polymer-conjugated IL-15 (NKTR-255) induced CD8+ and CD4+ T-cell and natural killer cell proliferation in nonhuman primates.•NKTR-255 enhanced the efficacy of…”
Get full text

CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study by Gazeau, Nicolas, Fiorenza, Salvatore, Kimble, Erik L., Vinaud Hirayama, Alexandre, Pender, Barbara S., Di, Henna A., Kirchmeier, Delaney R., Till, Brian G., Shadman, Mazyar, Riddell, Stanley R., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan

Get full text

Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma by Vinaud Hirayama, Alexandre, Fiorenza, Salvatore, Gauthier, Jordan, Voutsinas, Jenna M., Wu, Qian Vicky, Kimble, Erik L., Pender, Barbara S., Kirchmeier, Delaney R., Di, Henna A., Cassaday, Ryan D., Chapuis, Aude G., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

Get full text

Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II Study by Gazeau, Nicolas, Fiorenza, Salvatore, Kimble, Erik, Hirayama, Alexandre V., Pender, Barbara S., Di, Henna A, Kirchmeier, Delaney R, Till, Brian G., Shadman, Mazyar, Riddell, Stanley R., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan

Get full text

15 - Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II Study by Gazeau, Nicolas, Fiorenza, Salvatore, Kimble, Erik, Hirayama, Alexandre V., Pender, Barbara S., Di, Henna A, Kirchmeier, Delaney R, Till, Brian G., Shadman, Mazyar, Riddell, Stanley R., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan

Get full text

124 - Phase I Trial of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder for Adults with Relapsed/Refractory B-ALL by Gauthier, Jordan, Gazeau, Nicolas, Fiorenza, Salvatore, Kimble, Erik, Hirayama, Alexandre V., Pender, Barbara S., Di, Henna A, Kirchmeier, Delaney R, Shadman, Mazyar, Cassaday, Ryan D., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

Get full text

Phase I Trial of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder for Adults with Relapsed/Refractory B-ALL by Gauthier, Jordan, Gazeau, Nicolas, Fiorenza, Salvatore, Kimble, Erik, Hirayama, Alexandre V., Pender, Barbara S., Di, Henna A, Kirchmeier, Delaney R, Shadman, Mazyar, Cassaday, Ryan D., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

Get full text

IL-15 Serum Concentrations and CD19 CAR T-Cell Therapy: Impact on Clinical Outcomes and In Vivo CAR T Cell Kinetics by Gauthier, Jordan, Chou, Cassie, Hirayama, Alexandre V., Fiorenza, Salvatore, Kimble, Erik, Wu, Qian, Voutsinas, Jenna M., Pender, Barbara S., Phi, Tinh-Doan, Jamieson, Abby W, Kirchmeier, Delaney R, Di, Henna A, Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

Get full text